BEACON THERAPEUTICS HOLDINGS LIMITED
Get an alert when BEACON THERAPEUTICS HOLDINGS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-08-31 (in 3mo)
Last made up 2025-08-17
Watchouts
Cash
£22M
Latest balance sheet
Net assets
£18M
Equity attributable
Employees
71
Average over period
Profit before tax
-£58M
Period ending 2024-12-31
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
The Group has sustained recurring net losses, as would be expected of a pre-revenue group focussing on the development of a ophthalmic gene therapy to restore the vision of patients, and is reliant on funding from investors. ... indicate that a material uncertainty exists that may cast significant doubt on the Group and parent company's ability to continue as a going concern.
Name history
Renamed 1 time since incorporation
- BEACON THERAPEUTICS HOLDINGS LIMITED 2023-06-01 → present
- SPL 123 LIMITED 2022-08-18 → 2023-06-01
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £221,609 | — | |
| Operating profit | -£49,122,210 | -£58,268,745 | |
| Profit before tax | -£49,805,768 | -£58,441,441 | |
| Net profit | -£48,601,990 | -£56,549,287 | |
| Cash | £11,917,976 | £21,529,033 | |
| Total assets less current liabilities | £59,007,820 | £52,798,761 | |
| Net assets | £20,294,238 | £17,706,393 | |
| Equity | £20,294,238 | £17,706,393 | |
| Average employees | 88 | 71 | |
| Wages | £14,209,714 | £11,353,775 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | -22166.2% | — | |
| Net margin | -21931.4% | — | |
| Return on capital employed | -83.2% | -110.4% | |
| Gearing (liabilities / total assets) | 70.3% | 70.2% | |
| Current ratio | 2.12x | 4.07x | |
| Interest cover | -54.58x | -76.72x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- Grant Thornton UK LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“The Group has sustained recurring net losses, as would be expected of a pre-revenue group focussing on the development of a ophthalmic gene therapy to restore the vision of patients, and is reliant on funding from investors. ... indicate that a material uncertainty exists that may cast significant doubt on the Group and parent company's ability to continue as a going concern.”
Group structure
- BEACON THERAPEUTICS HOLDINGS LIMITED · parent
- Beacon Therapeutics Limited 100%
- Beacon Therapeutics (USA), Inc. 100%
Significant events
- “On 3 July 2024, the Company announced it had raised $170m in Series B Funding. $75m of this funding was received upon closing, $35m was received in April 2025 with the balance expected to be received in the fourth quarter of 2025.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
9 active · 4 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BALDO, Lance | Director | 2024-10-03 | Oct 1972 | American |
| CHESTER, Cariad Dixon | Director | 2024-07-03 | Jul 1991 | American |
| FAROOQ, Khurem Arif | Director | 2023-05-01 | Feb 1967 | British |
| FELLOWS, David Andrew | Director | 2023-03-31 | Aug 1956 | American |
| HOLLOWOOD, Christopher John, Dr | Director | 2022-08-18 | Dec 1974 | British |
| HRISTODOROV, Dimitrij, Dr | Director | 2024-07-03 | May 1986 | German |
| JOUSTRA, Wouter Sebastian James | Director | 2024-07-03 | Jul 1988 | Dutch |
| PETRIS, Elisa Michela, Dr | Director | 2022-08-18 | Jan 1979 | Italian,Canadian |
| WALSH, Colin, Dr. | Director | 2025-12-23 | May 1985 | American |
Show 4 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| JOHN, Markus Robert, Dr | Director | 2023-03-31 | 2024-07-03 |
| KAPLAN, Lester, Dr | Director | 2023-05-01 | 2025-12-21 |
| MACLAREN, Robert Edward, Dr | Director | 2023-03-31 | 2024-07-03 |
| SMIRNYAGINA, Ekaterina, Dr | Director | 2023-03-31 | 2024-07-03 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Syncona Limited | Corporate entity | Shares 25–50%, Voting 25–50% | 2022-08-18 | Active |
Filing timeline
Last 20 of 58 total filings
Material constitutional events — rename, articles re-file, resolution
- 2026-02-04 RP04SH01 Legacy
- 2026-01-19 RP04SH01 Legacy
- 2026-01-05 RESOLUTIONS Resolution
- 2026-01-05 MA Memorandum articles
- 2025-11-03 RESOLUTIONS Resolution
- 2025-11-03 MA Memorandum articles
- 2025-04-30 MA Memorandum articles
- 2025-04-30 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-12 | SH01 | capital | Capital allotment shares | |
| 2026-02-04 | RP04SH01 | change-of-name | Legacy | |
| 2026-01-20 | SH01 | capital | Capital allotment shares | |
| 2026-01-19 | RP04SH01 | change-of-name | Legacy | |
| 2026-01-05 | TM01 | officers | Termination director company with name termination date | |
| 2026-01-05 | RESOLUTIONS | resolution | Resolution | |
| 2026-01-05 | MA | incorporation | Memorandum articles | |
| 2025-12-24 | AP01 | officers | Appoint person director company with name date | |
| 2025-11-06 | SH01 | capital | Capital allotment shares | |
| 2025-11-06 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2025-11-03 | RESOLUTIONS | resolution | Resolution | |
| 2025-11-03 | MA | incorporation | Memorandum articles | |
| 2025-08-26 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-06-06 | AA | accounts | Accounts with accounts type group | |
| 2025-05-16 | SH01 | capital | Capital allotment shares | |
| 2025-04-30 | MA | incorporation | Memorandum articles | |
| 2025-04-30 | RESOLUTIONS | resolution | Resolution | |
| 2024-10-16 | AA | accounts | Accounts with accounts type group | |
| 2024-10-15 | AP01 | officers | Appoint person director company with name date | |
| 2024-09-12 | CS01 | confirmation-statement | Confirmation statement with updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 15
- Capital events
- 4
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31